Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease

Experimental Neurology

Volumn 184, Issue 1, 2003, Pages 521-529

  Van Kampen, Jackalina ^a   Robertson, Harold ^b   Hagg, Theo ^a   Drobitch, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

G115; Ginseng; MPP+; MPTP; Neuroprotection; Parkinson; Rat; Rotation

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GINSENG EXTRACT; NEUROTOXIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DRUG MECHANISM; DRUG SCREENING; EXPOSURE; FEMALE; GINSENG; LOCOMOTION; METABOLITE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0345257309     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.08.002     Document Type: Article

References (47)

1. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch. Neurol. 32:1975;114-118.
2. Beal M.F., Brouillet E., Jenkins B., Henshaw R., Rosen B., Hyman B.T. Age-dependent striatal excitoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61:1993;1147-1150.
3. Berg D., Roggendorf W., Schroder U., Klein R., Tatschner T., Benz P., Tucha O., Preier M., Lange K.W., Reiners K., Gerlach M., Becker G. Echogenicity of the substantia nigra association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 59:2002;999-1005.
4. Bockelmann R., Wolf G., Ransmayr G., Riederer P. NADPH-diaphorase/nitric oxide synthase containing neruons in normal and Parkinson's disease putamen. J. Neural Transm. Park. Dis. Dement. Sect. 7:1994;115-121.
5. Brouillet E., Beal M.F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport. 4:1993;387-390.
6. Cadet J.L., Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 32:1998;117-131.
7. Calne D.B. The nature of Parkinson's disease. Neurochem. Int. 20:1992;1S-3S.
8. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
9. Dexter D.T., Wells F.R., Lees A., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
10. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;14669-14674.
11. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease evidence supporting it. Ann. Neurol. 32:1992;804-812.
12. Foley P., Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J. Neurol. 247:2000;II82-II94.
13. Fukunaga K., Miyamoto E. Role of MAP kinase in neurons. Mol. Neurobiol. 16:1998;79-95.
14. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity evidence from mice lacking the transporter. J. Neurochem. 69:1997;1322-1325.
15. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14:1993;43-49.
16. Hattori N., Tanaka M., Ozawa T., Mizuno Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30:1991;563-571.
17. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease an x-ray microanalysis. J. Neurochem. 56:1991;446-451.
18. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19:1999;3440-3447.
19. Javitch J.A., D'amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine uptake of the metabolite N-methyle-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA. 82:1985;2173-2177.
20. Jiang F., Desilva S., Turnbull J. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J. Neurol. Sci. 180:2000;52-54.
21. Kim Y.C., Kim S.R., Markelonis G.J., Oh T.H. Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. J. Neurosci. Res. 53:1998;426-432.
22. Kish S.J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58:1985;343-346.
23. Kitts D.D., Wijewickreme A.N., Hu C. Antioxidant properties of a North American ginseng extract. Mol. Cell. Biochem. 203:2000;1-10.
24. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16:2000;724-739.
25. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine intoxication in mouse. Exp. Neurol. 156:1999;50-61.
26. Lange K.W., Loschmann P.A., Sofic E., Burg M., Horowski R., Kalveram K.T., Wachtel H., Riederer P. The competetive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch. Pharmacol. 348:1993;586-592.
27. Lee F.C. Facts About Ginseng, The Elixir of Life. 1992;Hollyn International Corporation, New Jersey.
28. Liao B., Newmark H., Zhou R. Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp. Neurol. 173:2002;224-234.
29. Lim J.H., Wen T.C., Matsuda S., Tanaka J., Maeda N., Peng H., Aburaya J., Ishihara K., Sakanaka M. Protection of ischemic hippocampal neurons by ginsenoside Rb1, a main ingredient of ginseng root. Neurosci. Res. 28:1997;191-200.
30. Liu M., Zhang J.T. Protective effects of ginsenoside Rb1 and Rg1 on cultured hippocampal neurons. Yao Xue Xue Bao. 30:1995;674-678.
31. Mattson M.P., Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromol. Med. 2:2002;215-231.
32. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. 60:2000;277-290.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
34. Poirier J., Dea D., Baccichet A., Thiffault C. Superoxide dismutase expression in Parkinson's disease. Ann. NY Acad. Sci. 738:1994;116-120.
35. Rudakewich M., Ba F., Benishin C.G. Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). Planta Med. 67:2001;533-537.
36. Saito H. Recent Advances in Ginseng Studies. 1990;Kirokawa Publishing Company, Tokyo.
37. Salim K.N., Mcewen B.S., Chao H.M. Ginsenoside Rb1 regulates ChAT, NGF and trkA mRNA expression in the rat brain. Brain Res. Mol. Brain Res. 47:1997;177-182.
38. Schapira A.H., Cooper J.M., Dexter D.T., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
39. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174:1997;193-197.
40. Shimoke K., Chiba H. Nerve growth factor prevents 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells relevance to therapeutical application for Parkinson's disease. J. Neurosci. Res. 63:2001;402-409.
41. Siddique M.S., Eddeb F., Mantle D., Mendelow A.D. Extracts of Ginkgo biloba and Panax ginseng protect brain proteins from free radical induced oxidative damage in vitro. Acta Neurochir. 76:2000;87-90.
42. Tanner C.M., Ben-Shlomo Y. Epidemiology of Parkinon's disease. Adv. Neurol. 80:1999;153-159.
43. Tsang D., Yeung H.W., Tso W.W., Peck H. Ginseng saponins influence on neurotransmitter uptake in rat brain synaptosomes. Planta Med. 3:1985;221-224.
44. Van Kampen J.M., Mcgeer E.G., Stoessl A.J. Dopamine transporter function assessed by antisense knockdown in the rat protection from dopamine neurotoxicity. Synapse. 37:2000;171-178.
45. Wang C.N., Shiao Y.J., Kuo Y.H., Chen C.C., Lin Y.L. Inducible nitric oxide synthase inhibitors from Saposhnikovia divaricata and Panax quinquefolium. Planta Med. 66:2000;644-647.
46. Yu S.C., Li X.Y. Effect of ginsenoside on IL-1 beta and IL-6 mRNA expression in hippocampal neurons in chronic inflammation model of aged rats. Acta Pharmacol. Sin. 21:2000;915-918.
47. Zimmer L., Kodas E., Guilloteau D., Garreau L., Besnard J.-C., Chalon S. Microdialysis as a tool for in vivo study of dopamine transporter function in rat brains. J. Neurosci. Methods. 103:2000;137-144.